<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03149718</url>
  </required_header>
  <id_info>
    <org_study_id>PRO17010410</org_study_id>
    <secondary_id>R21DA043735</secondary_id>
    <nct_id>NCT03149718</nct_id>
  </id_info>
  <brief_title>Community Pharmacists and Opioid Misuse</brief_title>
  <official_title>Prescription Opioid Misuse: Pharmacist-Delivered Intervention at Point of Service</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Opioid medication misuse and overdose have reached epidemic proportions in the US. Community&#xD;
      pharmacy is a potentially valuable resource for addressing opioid medication misuse. This&#xD;
      study will manualize and establish the feasibility, acceptability, and clinical effect of a&#xD;
      community pharmacist-led intervention aimed at: improving opioid mediation regimen adherence,&#xD;
      eliminating misuse, connecting patients to additional care, and safeguarding against&#xD;
      overdose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current small scale single-blinded randomized controlled study will build on our&#xD;
      preliminary studies by manualizing and examining the feasibility, acceptability, and clinical&#xD;
      effect for the Brief Intervention Medication Therapy Management (BI-MTM) model. BI-MTM is a&#xD;
      multicomponent community pharmacy-based intervention. BI-MTM is designed to: (1) promote&#xD;
      opioid medication regimen adherence, (2) reduce opioid medication misuse, (3) connect&#xD;
      participants with patient navigation (a chronic condition care model) to increase&#xD;
      self-management of health conditions that increase risk for misuse, and (4) provide naloxone&#xD;
      rescue training referrals. Patients will be screened across 14 months for opioid medication&#xD;
      misuse in an urban community pharmacy affiliated with a major medical system. Patients&#xD;
      positive for misuse will be randomly assigned to BI-MTM (n=23) or Standard Medication&#xD;
      Counseling (n=23). Standard Medication Counseling is the Centers for Medicaid and Medicare&#xD;
      Services requirement for pharmacists in the US wherein pharmacy patients filling&#xD;
      prescriptions receive information and opt-in counseling. This study will demonstrate&#xD;
      feasibility and acceptability of BI-MTM for community pharmacy patients who misuse their&#xD;
      opioid medications for future intervention implementation in a fully powered randomized&#xD;
      trial. This study will also generate preliminary data regarding opioid medication misuse&#xD;
      elimination and increases in participant self-management activation for comorbid health&#xD;
      conditions that increase risk for misuse.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2017</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">March 27, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intervention feasibility</measure>
    <time_frame>Month 21 of Study</time_frame>
    <description>Intervention feasibility will be established through delivery of all BI-MTM components to 85% of BI-MTM recipients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intervention acceptability</measure>
    <time_frame>Month 21 of Study</time_frame>
    <description>Intervention acceptability will be demonstrated though qualitative interviews.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid Misuse</measure>
    <time_frame>Month 21 of Study</time_frame>
    <description>Opioid misuse will be demonstrated by the Prescription Opioid Misuse Index (POMI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Self-Management</measure>
    <time_frame>Month 21 of Study</time_frame>
    <description>Patient self-management activation misuse than will be captured by the Patient Activation Measure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Opioid Misuse</condition>
  <arm_group>
    <arm_group_label>SMC (n=23)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Medication Counseling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI-MTM (n=23)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brief Intervention Medication Therapy Management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Brief Intervention Medication Therapy Management</intervention_name>
    <description>BI-MTM is designed to: (1) eliminate opioid medication misuse, (2) promote opioid regimen adherence, (3) connect participants with Patient Navigation to increase patient self-management activation for health conditions that increase risk for misuse (Patient Navigation is an evidence-based chronic care intervention), and (4) provide naloxone rescue training referrals.</description>
    <arm_group_label>BI-MTM (n=23)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard Medication Counseling (SMC)</intervention_name>
    <description>Standard Medication Counseling (SMC; n=23; i.e., treatment-as-usual condition). Standard Medication Counseling is the Centers for Medicaid and Medicare Services requirement for pharmacists in the US wherein pharmacy patients filling prescriptions receive information and opt-in counseling.</description>
    <arm_group_label>SMC (n=23)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Opioid Misuse&#xD;
&#xD;
             -≥18 years&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are pregnant (given potential pre/post-natal opioid use complications among pregnant&#xD;
             women/offspring)&#xD;
&#xD;
          -  Cannot provide collateral contact information for ≥2 contact persons (to ensure&#xD;
             consistent contact/follow up)&#xD;
&#xD;
          -  Do not have a reliable landline or mobile phone to be contacted by study staff&#xD;
&#xD;
          -  Are only filling buprenorphine (given some formulations are not indicated for pain)&#xD;
&#xD;
          -  Plan to leave the area for an extended period of time in the next 3 months&#xD;
&#xD;
          -  Have had a psychotic and/or manic episode in the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald Cochran, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Falk Pharmacy</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicine Shoppe</name>
      <address>
        <city>Somerset</city>
        <state>Pennsylvania</state>
        <zip>15501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Jerry Cochran</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Pharmacy</keyword>
  <keyword>Intervention</keyword>
  <keyword>Medication Adherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

